Neumedicines

Focus: Neumedicines is an early-stage immunology-focused biotech founded in 2019, specializing in IL-12-based therapeutic treatments for cancer and rare diseases. The company is pre-revenue with a pipeline concentrated in Phase 2 development.

Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Neumedicines

AI assessmentNot Hiring

No open roles listed right now. Follow Neumedicines to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

HemaMax

Hematopoietic Syndrome Due to Acute Radiation Syndrome

Phase 1

HemaMax

Hematopoietic Syndrome Due to Acute Radiation Syndrome

Phase 2

Help build intelligence for Neumedicines

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a focused biotech with proprietary IL-12 platform technology in high-value immunology space
Exposure to multiple therapeutic areas (lymphoma, radiation syndrome, cutaneous T-cell lymphoma) with diverse clinical programs
Early-stage environment offers direct impact on drug development and potential equity upside if pipeline advances

Watch Out For

No active job openings currently listed, suggesting limited near-term hiring or potential organizational contraction
Pre-revenue status with unknown funding and cash position creates significant execution risk and burn rate uncertainty
All programs in Phase 1-2 with no Phase 3 data or regulatory milestones—5+ years minimum to potential approval

Generated by Claude from Neumedicines's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NM-IL-12

Colostomy Stoma

Phase 2

Clinical Trials (1)

NCT02544061NM-IL-12 (rHuIL-12) in Subjects With Open Surgical Wounds

Phase 2

NM-IL-12 and TSEBT

Cutaneous T Cell Lymphoma (CTCL)

Phase 2

Clinical Trials (1)

NCT02542124NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)

Phase 2

NM-IL-12

Lymphoma, Large B-Cell, Diffuse (DLBCL)

Phase 2

Clinical Trials (1)

NCT02544724NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Founded: 2019

Portfolio: 3 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

2 pipeline

Marketed

Pipeline